Cargando…

Placebo-Controlled Effectiveness of Idiopathic Normal Pressure Hydrocephalus Shunting: A Randomized Pilot Trial

Multiple prospective nonrandomized studies have shown 60% to 70% of patients with idiopathic normal pressure hydrocephalus (iNPH) improve with shunt surgery, but multicenter placebo-controlled trial data are necessary to determine its effectiveness. OBJECTIVE: To evaluate the effectiveness of cerebr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luciano, Mark, Holubkov, Richard, Williams, Michael A., Malm, Jan, Nagel, Sean, Moghekar, Abhay, Eklund, Anders, Zwimpfer, Thomas, Katzen, Heather, Hanley, Daniel F., Hamilton, Mark G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2023
Materias:	CSF Diversion Procedures: Ventriculoperitoneal Shunt
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9904195/ https://www.ncbi.nlm.nih.gov/pubmed/36700738 http://dx.doi.org/10.1227/neu.0000000000002225

Ejemplares similares

Pulmonary Arterial Hypertension in a Patient with a Portosystemic Shunt: Diagnostic Challenge
por: Stepffer, Carolina, et al.
Publicado: (2020)

Clinical predictors of shunt response in the diagnosis and treatment of idiopathic normal pressure hydrocephalus: a systematic review and meta-analysis
por: Thavarajasingam, Santhosh G., et al.
Publicado: (2021)

The diagnostic value of the pulsatility curve to predict shunt responsiveness in patients with idiopathic normal pressure hydrocephalus
por: van Bilsen, M. W. T., et al.
Publicado: (2022)

Cerebrospinal fluid and venous biomarkers of shunt-responsive idiopathic normal pressure hydrocephalus: a systematic review and meta-analysis
por: Thavarajasingam, Santhosh G., et al.
Publicado: (2022)

Radiological predictors of shunt response in the diagnosis and treatment of idiopathic normal pressure hydrocephalus: a systematic review and meta-analysis
por: Thavarajasingam, Santhosh G., et al.
Publicado: (2022)

Gait, falls, cognitive function, and health-related quality of life after shunt-treated idiopathic normal pressure hydrocephalus—a single-center study
por: Hallqvist, Caroline, et al.
Publicado: (2022)

Motor skills, cognitive impairment, and quality of life in normal pressure hydrocephalus: early effects of shunt placement
por: Hülser, Matthias, et al.
Publicado: (2022)

Upper limb dysfunction and activities in daily living in idiopathic normal pressure hydrocephalus
por: Sirkka, Jani, et al.
Publicado: (2021)

Systematic volumetric analysis predicts response to CSF drainage and outcome to shunt surgery in idiopathic normal pressure hydrocephalus
por: Wu, Dan, et al.
Publicado: (2021)

Risk factors for subdural hematomas in patients shunted for idiopathic normal pressure hydrocephalus
por: Sundström, Nina, et al.
Publicado: (2015)

CSF Biomarkers Predict Gait Outcomes in Idiopathic Normal Pressure Hydrocephalus
por: Darrow, Jacqueline A., et al.
Publicado: (2022)

The ASPECT Hydrocephalus System: a non-hierarchical descriptive system for clinical use
por: Milan, Joachim Birch, et al.
Publicado: (2022)

Paradoxical response of intracranial pressure to shunt valve setting adjustments
por: D’Antona, Linda, et al.
Publicado: (2020)

Surgical treatment of symptomatic pineal cysts without hydrocephalus—meta-analysis of the published literature
por: Masina, Riccardo, et al.
Publicado: (2021)

Shunt infusion studies: impact on patient outcome, including health economics
por: Lalou, Afroditi-Despina, et al.
Publicado: (2020)

Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study
por: Leung, Yuk Yee, et al.
Publicado: (2015)

Cerebrospinal fluid ratios with Aβ(42) predict preclinical brain β-amyloid accumulation
por: Racine, Annie M., et al.
Publicado: (2015)

Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics
por: Teunissen, Charlotte E., et al.
Publicado: (2016)

Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants
por: Li, Wei, et al.
Publicado: (2017)

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease
por: Dekker, Alain D., et al.
Publicado: (2017)

Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios
por: Toombs, Jamie, et al.
Publicado: (2018)

Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project
por: Willemse, Eline A.J., et al.
Publicado: (2018)

Derivation of cutoffs for the Elecsys(®) amyloid β (1–42) assay in Alzheimer's disease
por: Shaw, Leslie M., et al.
Publicado: (2018)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Cerebrospinal fluid collection: An informative animation video for patients and caregivers
por: Babapour Mofrad, R., et al.
Publicado: (2019)

CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume
por: Düzel, Emrah, et al.
Publicado: (2018)

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease
por: Kruse, Niels, et al.
Publicado: (2018)

Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma
por: Koch, Manja, et al.
Publicado: (2017)

A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging
por: Mo, Yi, et al.
Publicado: (2017)

Consensus guidelines for lumbar puncture in patients with neurological diseases
por: Engelborghs, Sebastiaan, et al.
Publicado: (2017)

Lumbar puncture in patients with neurologic conditions
por: Babapour Mofrad, Rosha, et al.
Publicado: (2017)

Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios
por: Marelli, Cecilia, et al.
Publicado: (2015)

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?
por: Paterson, Ross W., et al.
Publicado: (2015)

Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia
por: Forlenza, Orestes V., et al.
Publicado: (2015)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ(1-42), T-tau, and P-tau values
por: Willemse, Eline A.J., et al.
Publicado: (2017)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ(42/40) ratio
por: Pouclet-Courtemanche, Hélène, et al.
Publicado: (2019)

Revision and complication rates in adult shunt surgery: a single-institution study
por: Mansoor, Nadia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0h66qgtlpk0h52v30d8t4jjg2u